8-K: Traws Pharma Receives Favorable FDA Guidance for Bird Flu Drug, Pursues Strategic Stockpiling

Traws Pharma, Inc. announced it has received detailed guidance from the FDA regarding the development of its investigational bird flu and seasonal flu product candidate, tivoxavir marboxil, and is initiating discussions for national and international stockpiling.

Summary

• Traws Pharma received written feedback from the U.S. Food and Drug Administration (FDA) on development paths for tivoxavir marboxil (TXM) for bird flu and seasonal flu, including the use of the Animal Rule.
• The company is pursuing discussions with the Biomedical Advanced Research and Development Authority (BARDA) for U.S. strategic stockpiling of TXM, estimated at 300 million to 600 million doses, and plans to engage international regulatory agencies.
• TXM demonstrated protection against mortality and disease in three preclinical animal models (mice, ferrets, non-human primates) for bird flu (H5N1), including the A/Texas/37/2024 strain, showing 100% protection against lethal challenge in mice and complete viral clearance in the lung.
• A single dose of TXM maintained plasma levels above the EC90 for approximately 3 weeks in Phase 1 human studies with good safety and tolerability.
• In ferrets, TXM dose-dependently increased survival (50% at 240mg human equivalent, 30% at 120mg human equivalent vs. 0% for control) and reduced lung virus burden and pathology.
• In non-human primates, a single oral dose of TXM significantly lowered lung virus burden and prevented virus-induced weight loss.
• Traws Pharma's other key program, Ratutrelvir for COVID-19, is a ritonavir-independent main protease inhibitor, with Phase 1 studies showing good safety and sustained drug levels above EC90 for 10 days.
• Ratutrelvir is consistently more potent than competitor agents (nirmatrelvir, ibuzatrelvir) in suppressing COVID in vitro and is active against strains resistant to PAXLOVID or ensitrelvir.
• Cash, cash equivalents, and short-term investments as of March 31, 2025, were $15.9 million, expected to support planned operations into Q1 2026.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to favorable FDA guidance, robust preclinical and early clinical data for TXM, and the initiation of discussions for government stockpiling, which represents a significant market opportunity. The progress with the COVID program (Ratutrelvir) also adds to the positive outlook. The primary concern is the limited cash runway, which implies a future capital raise.

Positives

• Positive FDA guidance received for TXM development, including potential use of the Animal Rule for accelerated approval, which is intended for situations where human clinical studies are unethical or impractical.
• Strong preclinical efficacy data for TXM in three animal models (mice, ferrets, NHPs) against H5N1 bird flu, showing protection against mortality, reduced viral burden, and improved pathology.
• Phase 1 human data for TXM shows a single dose maintains plasma levels above EC90 for approximately 3 weeks with good safety, supporting its potential as a single-dose therapy for treatment or prophylaxis.
• TXM is broadly effective against bird flu strains, including the Texas dairy worker strain, and has a large safety window enabling use of higher doses if needed for future emergent resistant strains.
• Initiated discussions with BARDA for U.S. strategic stockpiling of TXM, targeting an estimated 300 million to 600 million doses, and plans to engage international agencies, indicating significant market potential and government interest.
• Ratutrelvir (COVID-19 program) shows superior in vitro potency against various SARS-CoV2 strains and activity against strains resistant to existing therapies like PAXLOVID or ensitrelvir.
• Ratutrelvir's ritonavir-independent regimen mitigates patient exclusion due to drug-drug interactions, potentially expanding patient access to protease inhibitor therapy.
• Ratutrelvir's 10-day dosing regimen has the potential to prevent both COVID-rebound and Long COVID, addressing known limitations of current treatments.
• The company has an experienced team and support from recognized institutional investors, including OrbiMed and Perceptive Advisors.

Negatives

• The company's cash position of $15.9 million as of March 31, 2025, is projected to support operations only into Q1 2026, indicating a need for future capital.
• Legacy oncology assets (rigosertib and narazaciclib) are being progressed for business development exit strategies, suggesting a divestment or non-core focus.
• The document contains forward-looking statements that involve substantial risks and uncertainties, including the inability to obtain sufficient additional capital.

Risks

• Uncertainties associated with Traws' product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement and completion of clinical trials, studies, and evaluations.
• Risks related to the inability of Traws to obtain sufficient additional capital to continue to advance its product candidates and operate its business.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from product candidates currently being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market.
• Uncertainties in retaining key personnel, including the executive team and directors.
• Risks that may stem from changes in the regulatory, economic, and/or political landscape.
• Disruption and volatility in the global currency, capital, and credit markets.
• Risks associated with the possible failure to realize certain anticipated benefits of Traws' 2024 merger with Trawsfynydd Therapeutics, Inc.
• The extent of the spread and threat of the bird flu.

Future Outlook

Traws Pharma plans to continue discussions with the FDA and other regulatory agencies to finalize the development path for TXM for bird and seasonal flu, including pursuing accelerated approval via the Animal Rule. The company also intends to engage BARDA and international agencies for TXM stockpiling. For Ratutrelvir, a briefing document is planned for submission to regulatory authorities in Q2 2025 for acute COVID treatment, rebound prevention, and Long COVID. The company expects its current cash to fund operations into Q1 2026.

Management Comments

• "We are requesting a Type D meeting with the FDA to specify next steps and look forward to working closely with the Agency to develop TXM for bird flu and seasonal flu." C. David Pauza, PhD, Chief Science Officer.
• "The consistent finding of therapeutic effects of TXM in three animal models of bird flu increases our confidence that this compound should be rapidly progressed for stockpiling and pandemic readiness by government agencies." Robert R. Redfield, MD, Chief Medical Officer and former CDC Director.
• "To that end, we have initiated a dialog with the Biomedical Advanced Research and Development Authority (BARDA), the responsible agency for stockpiling for pandemic preparedness in the United States, and we plan to engage with respective international regulatory agencies for the same purpose. With the known history that previous H5N1 virus outbreaks in human populations are associated with death rates of up to 50%, we believe that these actions should be pursued with great urgency." Robert R. Redfield, MD.
• "This initial interaction with the FDA has helped guide the development of TXM as a broad therapeutic against pandemic and seasonal influenza. We are committed to progressing the process for stockpiling TXM to prevent any pandemic outbreaks associated with bird flu." Iain Dukes MA DPhil, Interim CEO.

Industry Context

The announcement highlights Traws Pharma's focus on small molecule antiviral drugs, a significant growth sector in biopharma, as evidenced by blockbuster revenues from existing antivirals like BIKTARVY ($13.4B in 2024) and PAXLOVID ($5.7B in 2024). The company aims to address critical unmet needs in respiratory viral diseases, particularly bird flu, where no approved therapies exist and historical human mortality rates are high, and COVID-19, where current therapies have limitations like drug-drug interactions and rebound risk. The waning use of vaccines and regulatory hurdles for new vaccine approvals further underscore the critical role of antivirals in pandemic preparedness and public health.

Comparison to Industry Standards

• TXM's broad potency against many viral strains, including those resistant to Tamiflu and Xofluza, positions it favorably against current influenza treatments.
• Ratutrelvir's superior in vitro suppression of COVID versus benchmarks like nirmatrelvir (active in PAXLOVID) and emerging candidates like ibuzatrelvir, along with its activity against PAXLOVID or ensitrelvir resistant strains, suggests a potential best-in-class profile.
• Ratutrelvir's ritonavir-independent regimen addresses a key limitation of PAXLOVID, which is contraindicated in vulnerable populations due to drug-drug interactions, potentially offering broader accessibility.
• The proposed 10-day dosing regimen for Ratutrelvir, compared to PAXLOVID's 5-day regimen, aims to prevent clinical rebound and Long COVID, addressing known issues with existing treatments.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive regulatory progress, strong preclinical data, and large market opportunities (stockpiling, seasonal flu, COVID). However, there is a dilution risk from a potential future capital raise.
• Patients: Potential for new, effective treatments for bird flu, seasonal flu, and COVID-19, especially for those who cannot use existing therapies due to drug-drug interactions or resistance.
• Governments/Public Health Agencies: TXM could become a critical component of national and international pandemic preparedness strategies, offering a single-dose, potent antiviral for bird flu.
• Employees: Continued employment and potential growth opportunities as programs advance.

Next Steps

• Request a Type D meeting with the FDA to specify next steps for TXM development for bird flu and seasonal flu.
• Continue discussions with FDA and other regulatory agencies to finalize the development path for TXM.
• Continue discussions with BARDA on adding TXM to the strategic stockpile.
• Initiate dialogue with international regulatory agencies responsible for drug stockpiling for pandemic preparedness.
• Submit a briefing document to regulatory authorities in Q2 2025 for Ratutrelvir for acute COVID treatment/rebound prevention & Long COVID.
• Progress business development exit strategies for legacy oncology assets (rigosertib and narazaciclib).
• Expected to enroll approximately 90 influenza-positive subjects in a Phase 2a Seasonal Flu Study in Australia and South East Asia.
• Concurrent tablet formulation development for TXM, with a bioequivalence bridging study.

Key Dates

Recommendation

Keywords

Traws Pharma, TXM, tivoxavir marboxil, bird flu, H5N1, seasonal flu, influenza, antiviral, FDA, Animal Rule, BARDA, stockpiling, pandemic preparedness, Ratutrelvir, COVID-19, Long COVID, biopharmaceutical, clinical-stage, respiratory viral diseases, drug development, infectious disease